Covid19 Clinical Trial
Official title:
A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy Of S-1226 In Hospitalized Subjects With Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Verified date | February 2021 |
Source | SolAeroMed Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with moderate severity COVID-19 Bronchiolitis/Pneumonia.
Status | Suspended |
Enrollment | 30 |
Est. completion date | December 31, 2021 |
Est. primary completion date | October 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Subjects must meet the following criteria to be included in the study: 1. Male or Females between 18-80 years of age at the time of consent. 2. Laboratory-confirmed COVID-19 infection 3. Hospitalized for COVID-19 with clinical evidence of respiratory involvement, including at least one of the following: 1. Symptoms/Signs: cough, respiratory distress, increased work of breathing 2. Radiology: Chest radiograph or other chest imaging demonstrating one of bronchial thickening, increased secretions, hyperinflation, infiltrates 4. Hypoxemia in room air, SpO2 = 90% 5. Patient belongs to one of the following two categories in the seven-point COVID-19 severity scale: 1. Requiring supplemental oxygen by nasal prongs - Level 4 of the seven-point COVID-19 severity scale; 2. Requiring nasal high-flow oxygen therapy,- limited to this one component of Level 5 of the seven-point COVID-19 severity scale. 6. For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during the study period. 7. Ability to sign informed consent or, when patient is not capable of doing so, informed consent can be signed by legal/authorized representative Exclusion Criteria: - Subjects to whom any of the following applies will be excluded from the study: 1. Pregnant or breastfeeding females. 2. Patients unable to receive S-1226; particularly if receiving oxygen therapy by face mask or non invasive ventilatory support 3. Patient requires Extracorporeal Membrane Oxygenation (ECMO) and/or invasive mechanical ventilation 4. Presence of any of the following abnormal laboratory values at screening: 1. Absolute neutrophil count (ANC) less than 0.5 x 109 / L. 2. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than 5 x upper limit of normal (ULN). 3. Platelets less than 50 x109 / L. 5. In the opinion of the investigator, progression to death is imminent and inevitable within the next 72 hours, irrespective of the provision of treatment. 6. Subject, who in the opinion of the Investigator, is unsuitable to participate |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Lung Function | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
SolAeroMed Inc. |
Canada,
El Mays TY, Choudhury P, Leigh R, Koumoundouros E, Van der Velden J, Shrestha G, Pieron CA, Dennis JH, Green FH, Snibson KJ. Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma. Respir Res. 2014 Sep 16;15:98. doi: 10.1186/s12931-014-0098-x. — View Citation
Green FH, Leigh R, Fadayomi M, Lalli G, Chiu A, Shrestha G, ElShahat SG, Nelson DE, El Mays TY, Pieron CA, Dennis JH. A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers. Trials. 2016 Jul 28;17:361. doi: 10.1186/s13063-016-1489-8. — View Citation
Swystun V, Green FHY, Dennis JH, Rampakakis E, Lalli G, Fadayomi M, Chiu A, Shrestha G, El Shahat SG, Nelson DE, El Mays TY, Pieron CA, Leigh R. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma. Trials. 2018 Jun 18;19(1):321. doi: 10.1186/s13063-018-2720-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Improvement in Thoracic Imaging as assessed by a Radiologist | Following treatment evidence of change in bronchial thickening, increased secretions, hyperinflation, infiltrates will be assessed at baseline and following treatment. These include Chest X-rays and CT Scans taken during the participant's hospital stay. | up to 28 days | |
Other | Number of Participants that develop of secondary pneumonia. | To be assessed following the completion of the study. | up to 28 days | |
Other | Viral load | if available | up to 28 days | |
Primary | Treatment Emergent Adverse Effects | The number and percent of treatment emergent adverse events will be monitored, recorded and graded for severity and assigned attribution. The severity will be assessed in the following manner:
Mild: Awareness of signs or symptoms, but are easily tolerated and are of minor irritant type, causing no limitations of usual activities. Signs or symptoms may require minor action or additional therapy. Moderate: Discomfort severe enough to cause some limitations of usual activities and may require action or additional therapy. Severe: Incapacitating with inability to carry out usual activities and requires specific action and/or medical attention. Note: the term severe is not the same as "serious", which is based on subject/event outcome or action criteria usually associated with events that pose a threat to a subject's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations. |
up to 28 days | |
Secondary | Change in use of supplemental oxygen therapy | Measured by comparing duration in which supplemental oxygen therapy is used at baseline and after drug administration. | up to 28 days | |
Secondary | Normalization of body temperature, measured in degrees Celsius. | This is an exploratory efficacy measure. Assessed by a return to a normal temperature range between 36.1 and 37.2 degrees Celsius for a period of 24 hours. | up to 28 days | |
Secondary | Evaluation of changes in an SpO2/FiO2 ratio | This is an exploratory efficacy measure. SpO2/FiO2 ratios of 235 and 315 correlate with PaO2/FiO2 ratios of 200 for Acute Respiratory Distress Syndrome and 300 for Acute Lung Injury. | up to 28 days | |
Secondary | Mean change on a 7-point ordinal scale | This is an exploratory efficacy measure. The average change in points from baseline for participants in the study.
Points 1-7 are defined below: not hospitalized with resumption of normal activities; not hospitalized, but unable to resume normal activities; hospitalized, not requiring supplemental oxygen; hospitalized, requiring supplemental oxygen; hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; hospitalized, requiring ECMO, invasive mechanical ventilation, or both; death. |
up to 28 days | |
Secondary | Proportion of patients that progress to levels 6-7 of the 7-point Ordinal Scale | This is an exploratory efficacy measure. Measured by the number of participants that progress from levels 6-7.
Points 1-7 are defined below: not hospitalized with resumption of normal activities; not hospitalized, but unable to resume normal activities; hospitalized, not requiring supplemental oxygen; hospitalized, requiring supplemental oxygen; hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; hospitalized, requiring ECMO, invasive mechanical ventilation, or both; death. |
up to 28 days | |
Secondary | Time to progression to levels 6-7 of the 7-point Ordinal Scale | This is an exploratory efficacy measure. Measured by the number of days by which a change in participant ordinal score is noted.
Points 1-7 are defined below: not hospitalized with resumption of normal activities; not hospitalized, but unable to resume normal activities; hospitalized, not requiring supplemental oxygen; hospitalized, requiring supplemental oxygen; hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; hospitalized, requiring ECMO, invasive mechanical ventilation, or both; death. |
up to 28 days | |
Secondary | Normalization of oxygen saturation, SpO2 > 90%, while breathing room air, sustained minimum 24 hours | This is an exploratory efficacy measure. Assessed by evaluations before and after the intervention has been administered. | up to 28 days | |
Secondary | Time to normalization of oxygen saturation, SpO2 > 90%, while breathing room air sustained minimum 24 hours. | This is an exploratory efficacy measure. Assessed by the duration required for oxygen saturation, SpO2, to be greater than 90%, while breathing room air and sustained for a minimum of 24 hours, following drug administration. | up to 28 days | |
Secondary | Change in daily symptom monitoring assessed by yes or no questions to a list of symptoms. | This is is an exploratory efficacy measure. Assessed by daily evaluations of signs and symptoms before and after the intervention has been administered. | up to 6 days | |
Secondary | Days of hospitalization attributable to COVID-19 disease | This is an exploratory efficacy measure. To be assessed by participants discharge date following treatment period. | up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |